nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Torsade de pointes—Vandetanib—thyroid cancer	0.0242	0.0242	CcSEcCtD
Solifenacin—Ileus—Vandetanib—thyroid cancer	0.024	0.024	CcSEcCtD
Solifenacin—Glaucoma—Vandetanib—thyroid cancer	0.0226	0.0226	CcSEcCtD
Solifenacin—Cystitis noninfective—Vandetanib—thyroid cancer	0.0166	0.0166	CcSEcCtD
Solifenacin—Cystitis—Vandetanib—thyroid cancer	0.0164	0.0164	CcSEcCtD
Solifenacin—Dry eye—Vandetanib—thyroid cancer	0.0157	0.0157	CcSEcCtD
Solifenacin—Bladder pain—Vandetanib—thyroid cancer	0.0154	0.0154	CcSEcCtD
Solifenacin—Faecaloma—Epirubicin—thyroid cancer	0.0148	0.0148	CcSEcCtD
Solifenacin—Faecalith—Epirubicin—thyroid cancer	0.0148	0.0148	CcSEcCtD
Solifenacin—Dysphonia—Sorafenib—thyroid cancer	0.0139	0.0139	CcSEcCtD
Solifenacin—Faecalith—Doxorubicin—thyroid cancer	0.0137	0.0137	CcSEcCtD
Solifenacin—Faecaloma—Doxorubicin—thyroid cancer	0.0137	0.0137	CcSEcCtD
Solifenacin—Atrial fibrillation—Vandetanib—thyroid cancer	0.013	0.013	CcSEcCtD
Solifenacin—Gastrooesophageal reflux disease—Sorafenib—thyroid cancer	0.0127	0.0127	CcSEcCtD
Solifenacin—Drug interaction—Sorafenib—thyroid cancer	0.0124	0.0124	CcSEcCtD
Solifenacin—Dry skin—Vandetanib—thyroid cancer	0.0113	0.0113	CcSEcCtD
Solifenacin—Influenza—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Solifenacin—Dysuria—Vandetanib—thyroid cancer	0.00997	0.00997	CcSEcCtD
Solifenacin—Infestation NOS—Vandetanib—thyroid cancer	0.0095	0.0095	CcSEcCtD
Solifenacin—Infestation—Vandetanib—thyroid cancer	0.0095	0.0095	CcSEcCtD
Solifenacin—Depression—Vandetanib—thyroid cancer	0.00948	0.00948	CcSEcCtD
Solifenacin—Renal failure—Vandetanib—thyroid cancer	0.00934	0.00934	CcSEcCtD
Solifenacin—Urinary tract infection—Vandetanib—thyroid cancer	0.00924	0.00924	CcSEcCtD
Solifenacin—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00899	0.00899	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00882	0.00882	CcSEcCtD
Solifenacin—Urinary tract disorder—Vandetanib—thyroid cancer	0.00842	0.00842	CcSEcCtD
Solifenacin—Urethral disorder—Vandetanib—thyroid cancer	0.00836	0.00836	CcSEcCtD
Solifenacin—Erythema multiforme—Vandetanib—thyroid cancer	0.00807	0.00807	CcSEcCtD
Solifenacin—Eye disorder—Vandetanib—thyroid cancer	0.00797	0.00797	CcSEcCtD
Solifenacin—Cardiac disorder—Vandetanib—thyroid cancer	0.00792	0.00792	CcSEcCtD
Solifenacin—Angiopathy—Vandetanib—thyroid cancer	0.00774	0.00774	CcSEcCtD
Solifenacin—Mediastinal disorder—Vandetanib—thyroid cancer	0.00769	0.00769	CcSEcCtD
Solifenacin—Dry skin—Sorafenib—thyroid cancer	0.00762	0.00762	CcSEcCtD
Solifenacin—Abdominal pain upper—Sorafenib—thyroid cancer	0.0076	0.0076	CcSEcCtD
Solifenacin—Mental disorder—Vandetanib—thyroid cancer	0.00747	0.00747	CcSEcCtD
Solifenacin—Malnutrition—Vandetanib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Solifenacin—Dysgeusia—Vandetanib—thyroid cancer	0.00727	0.00727	CcSEcCtD
Solifenacin—Vision blurred—Vandetanib—thyroid cancer	0.007	0.007	CcSEcCtD
Solifenacin—Cough—Vandetanib—thyroid cancer	0.00648	0.00648	CcSEcCtD
Solifenacin—Hypertension—Vandetanib—thyroid cancer	0.00641	0.00641	CcSEcCtD
Solifenacin—Infestation NOS—Sorafenib—thyroid cancer	0.00641	0.00641	CcSEcCtD
Solifenacin—Infestation—Sorafenib—thyroid cancer	0.00641	0.00641	CcSEcCtD
Solifenacin—Renal failure—Sorafenib—thyroid cancer	0.0063	0.0063	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00628	0.00628	CcSEcCtD
Solifenacin—Dry mouth—Vandetanib—thyroid cancer	0.00618	0.00618	CcSEcCtD
Solifenacin—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00606	0.00606	CcSEcCtD
Solifenacin—Infection—Vandetanib—thyroid cancer	0.00602	0.00602	CcSEcCtD
Solifenacin—Ileus—Epirubicin—thyroid cancer	0.00598	0.00598	CcSEcCtD
Solifenacin—Nervous system disorder—Vandetanib—thyroid cancer	0.00594	0.00594	CcSEcCtD
Solifenacin—Skin disorder—Vandetanib—thyroid cancer	0.00589	0.00589	CcSEcCtD
Solifenacin—Urinary tract disorder—Sorafenib—thyroid cancer	0.00568	0.00568	CcSEcCtD
Solifenacin—Connective tissue disorder—Sorafenib—thyroid cancer	0.00566	0.00566	CcSEcCtD
Solifenacin—Urethral disorder—Sorafenib—thyroid cancer	0.00564	0.00564	CcSEcCtD
Solifenacin—Ileus—Doxorubicin—thyroid cancer	0.00554	0.00554	CcSEcCtD
Solifenacin—Erythema multiforme—Sorafenib—thyroid cancer	0.00544	0.00544	CcSEcCtD
Solifenacin—Cardiac disorder—Sorafenib—thyroid cancer	0.00534	0.00534	CcSEcCtD
Solifenacin—Dyspepsia—Vandetanib—thyroid cancer	0.00534	0.00534	CcSEcCtD
Solifenacin—Decreased appetite—Vandetanib—thyroid cancer	0.00527	0.00527	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00523	0.00523	CcSEcCtD
Solifenacin—Fatigue—Vandetanib—thyroid cancer	0.00523	0.00523	CcSEcCtD
Solifenacin—Angiopathy—Sorafenib—thyroid cancer	0.00522	0.00522	CcSEcCtD
Solifenacin—Immune system disorder—Sorafenib—thyroid cancer	0.0052	0.0052	CcSEcCtD
Solifenacin—Mediastinal disorder—Sorafenib—thyroid cancer	0.00519	0.00519	CcSEcCtD
Solifenacin—Constipation—Vandetanib—thyroid cancer	0.00518	0.00518	CcSEcCtD
Solifenacin—Dysphonia—Epirubicin—thyroid cancer	0.00515	0.00515	CcSEcCtD
Solifenacin—Mental disorder—Sorafenib—thyroid cancer	0.00504	0.00504	CcSEcCtD
Solifenacin—Malnutrition—Sorafenib—thyroid cancer	0.00501	0.00501	CcSEcCtD
Solifenacin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00496	0.00496	CcSEcCtD
Solifenacin—Delirium—Epirubicin—thyroid cancer	0.00492	0.00492	CcSEcCtD
Solifenacin—Dysgeusia—Sorafenib—thyroid cancer	0.00491	0.00491	CcSEcCtD
Solifenacin—Abdominal pain—Vandetanib—thyroid cancer	0.00479	0.00479	CcSEcCtD
Solifenacin—Dysphonia—Doxorubicin—thyroid cancer	0.00476	0.00476	CcSEcCtD
Solifenacin—Angioedema—Sorafenib—thyroid cancer	0.00458	0.00458	CcSEcCtD
Solifenacin—Delirium—Doxorubicin—thyroid cancer	0.00456	0.00456	CcSEcCtD
Solifenacin—Cough—Sorafenib—thyroid cancer	0.00437	0.00437	CcSEcCtD
Solifenacin—Asthenia—Vandetanib—thyroid cancer	0.00435	0.00435	CcSEcCtD
Solifenacin—Hypertension—Sorafenib—thyroid cancer	0.00433	0.00433	CcSEcCtD
Solifenacin—Pruritus—Vandetanib—thyroid cancer	0.00429	0.00429	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00424	0.00424	CcSEcCtD
Solifenacin—Hepatocellular injury—Epirubicin—thyroid cancer	0.00424	0.00424	CcSEcCtD
Solifenacin—Dry mouth—Sorafenib—thyroid cancer	0.00417	0.00417	CcSEcCtD
Solifenacin—Hyperkalaemia—Epirubicin—thyroid cancer	0.00416	0.00416	CcSEcCtD
Solifenacin—Cystitis noninfective—Epirubicin—thyroid cancer	0.00414	0.00414	CcSEcCtD
Solifenacin—Cystitis—Epirubicin—thyroid cancer	0.00409	0.00409	CcSEcCtD
Solifenacin—Anaphylactic shock—Sorafenib—thyroid cancer	0.00409	0.00409	CcSEcCtD
Solifenacin—Infection—Sorafenib—thyroid cancer	0.00406	0.00406	CcSEcCtD
Solifenacin—Nervous system disorder—Sorafenib—thyroid cancer	0.00401	0.00401	CcSEcCtD
Solifenacin—Dizziness—Vandetanib—thyroid cancer	0.00401	0.00401	CcSEcCtD
Solifenacin—Skin disorder—Sorafenib—thyroid cancer	0.00397	0.00397	CcSEcCtD
Solifenacin—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00392	0.00392	CcSEcCtD
Solifenacin—Dry eye—Epirubicin—thyroid cancer	0.00391	0.00391	CcSEcCtD
Solifenacin—Vomiting—Vandetanib—thyroid cancer	0.00385	0.00385	CcSEcCtD
Solifenacin—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00385	0.00385	CcSEcCtD
Solifenacin—Bladder pain—Epirubicin—thyroid cancer	0.00383	0.00383	CcSEcCtD
Solifenacin—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00383	0.00383	CcSEcCtD
Solifenacin—Rash—Vandetanib—thyroid cancer	0.00382	0.00382	CcSEcCtD
Solifenacin—Dermatitis—Vandetanib—thyroid cancer	0.00382	0.00382	CcSEcCtD
Solifenacin—Headache—Vandetanib—thyroid cancer	0.0038	0.0038	CcSEcCtD
Solifenacin—Cystitis—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Solifenacin—Dry eye—Doxorubicin—thyroid cancer	0.00362	0.00362	CcSEcCtD
Solifenacin—Nausea—Vandetanib—thyroid cancer	0.0036	0.0036	CcSEcCtD
Solifenacin—Dyspepsia—Sorafenib—thyroid cancer	0.0036	0.0036	CcSEcCtD
Solifenacin—Decreased appetite—Sorafenib—thyroid cancer	0.00355	0.00355	CcSEcCtD
Solifenacin—Bladder pain—Doxorubicin—thyroid cancer	0.00354	0.00354	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00353	0.00353	CcSEcCtD
Solifenacin—Fatigue—Sorafenib—thyroid cancer	0.00352	0.00352	CcSEcCtD
Solifenacin—Constipation—Sorafenib—thyroid cancer	0.0035	0.0035	CcSEcCtD
Solifenacin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00334	0.00334	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00326	0.00326	CcSEcCtD
Solifenacin—Urticaria—Sorafenib—thyroid cancer	0.00325	0.00325	CcSEcCtD
Solifenacin—Abdominal pain—Sorafenib—thyroid cancer	0.00323	0.00323	CcSEcCtD
Solifenacin—Renal impairment—Epirubicin—thyroid cancer	0.00323	0.00323	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Solifenacin—Hypersensitivity—Sorafenib—thyroid cancer	0.00301	0.00301	CcSEcCtD
Solifenacin—Renal impairment—Doxorubicin—thyroid cancer	0.00299	0.00299	CcSEcCtD
Solifenacin—Asthenia—Sorafenib—thyroid cancer	0.00293	0.00293	CcSEcCtD
Solifenacin—Pruritus—Sorafenib—thyroid cancer	0.00289	0.00289	CcSEcCtD
Solifenacin—Liver function test abnormal—Epirubicin—thyroid cancer	0.00284	0.00284	CcSEcCtD
Solifenacin—Dry skin—Epirubicin—thyroid cancer	0.00282	0.00282	CcSEcCtD
Solifenacin—Abdominal pain upper—Epirubicin—thyroid cancer	0.00281	0.00281	CcSEcCtD
Solifenacin—Muscular weakness—Epirubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Solifenacin—Dizziness—Sorafenib—thyroid cancer	0.0027	0.0027	CcSEcCtD
Solifenacin—Influenza—Epirubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Solifenacin—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00263	0.00263	CcSEcCtD
Solifenacin—Dry skin—Doxorubicin—thyroid cancer	0.00261	0.00261	CcSEcCtD
Solifenacin—Vomiting—Sorafenib—thyroid cancer	0.0026	0.0026	CcSEcCtD
Solifenacin—Abdominal pain upper—Doxorubicin—thyroid cancer	0.0026	0.0026	CcSEcCtD
Solifenacin—Rash—Sorafenib—thyroid cancer	0.00258	0.00258	CcSEcCtD
Solifenacin—Dermatitis—Sorafenib—thyroid cancer	0.00258	0.00258	CcSEcCtD
Solifenacin—Headache—Sorafenib—thyroid cancer	0.00256	0.00256	CcSEcCtD
Solifenacin—Muscular weakness—Doxorubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Solifenacin—Dysuria—Epirubicin—thyroid cancer	0.00248	0.00248	CcSEcCtD
Solifenacin—Influenza—Doxorubicin—thyroid cancer	0.00246	0.00246	CcSEcCtD
Solifenacin—Nausea—Sorafenib—thyroid cancer	0.00243	0.00243	CcSEcCtD
Solifenacin—Infestation NOS—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Solifenacin—Infestation—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Solifenacin—Renal failure—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Solifenacin—Urinary tract infection—Epirubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Solifenacin—Dysuria—Doxorubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Solifenacin—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00224	0.00224	CcSEcCtD
Solifenacin—Infestation NOS—Doxorubicin—thyroid cancer	0.00219	0.00219	CcSEcCtD
Solifenacin—Infestation—Doxorubicin—thyroid cancer	0.00219	0.00219	CcSEcCtD
Solifenacin—Renal failure—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Solifenacin—Urinary tract infection—Doxorubicin—thyroid cancer	0.00213	0.00213	CcSEcCtD
Solifenacin—Pharyngitis—Epirubicin—thyroid cancer	0.00211	0.00211	CcSEcCtD
Solifenacin—Urinary tract disorder—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Solifenacin—Oedema peripheral—Epirubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Solifenacin—Connective tissue disorder—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Solifenacin—Urethral disorder—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Solifenacin—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Solifenacin—Erythema multiforme—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Solifenacin—Eye disorder—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Solifenacin—Cardiac disorder—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Solifenacin—Pharyngitis—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Solifenacin—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Solifenacin—Oedema peripheral—Doxorubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Solifenacin—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Solifenacin—Angiopathy—Epirubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Solifenacin—Urethral disorder—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Solifenacin—Immune system disorder—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Mediastinal disorder—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Solifenacin—Mental disorder—Epirubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Solifenacin—Erythema multiforme—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Solifenacin—Malnutrition—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Solifenacin—Eye disorder—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Solifenacin—Cardiac disorder—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Solifenacin—Dysgeusia—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Solifenacin—Angiopathy—Doxorubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Solifenacin—Immune system disorder—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Solifenacin—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Solifenacin—Vision blurred—Epirubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Solifenacin—Mental disorder—Doxorubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Solifenacin—Malnutrition—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Solifenacin—Dysgeusia—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Solifenacin—Palpitations—Epirubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Solifenacin—Cough—Epirubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Solifenacin—Vision blurred—Doxorubicin—thyroid cancer	0.00161	0.00161	CcSEcCtD
Solifenacin—Hypertension—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Solifenacin—Dry mouth—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Solifenacin—Confusional state—Epirubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Solifenacin—Palpitations—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Solifenacin—Anaphylactic shock—Epirubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Solifenacin—Infection—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Solifenacin—Cough—Doxorubicin—thyroid cancer	0.00149	0.00149	CcSEcCtD
Solifenacin—Nervous system disorder—Epirubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Solifenacin—Hypertension—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Solifenacin—Tachycardia—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Solifenacin—Skin disorder—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Solifenacin—Dry mouth—Doxorubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Solifenacin—Confusional state—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Solifenacin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.0014	0.0014	CcSEcCtD
Solifenacin—Infection—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Solifenacin—Nervous system disorder—Doxorubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Solifenacin—Tachycardia—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Solifenacin—Skin disorder—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Solifenacin—Somnolence—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Solifenacin—Dyspepsia—Epirubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Solifenacin—Decreased appetite—Epirubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Solifenacin—Fatigue—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Solifenacin—Constipation—Epirubicin—thyroid cancer	0.00129	0.00129	CcSEcCtD
Solifenacin—Feeling abnormal—Epirubicin—thyroid cancer	0.00125	0.00125	CcSEcCtD
Solifenacin—Somnolence—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Solifenacin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Solifenacin—Dyspepsia—Doxorubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Solifenacin—Decreased appetite—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Solifenacin—Fatigue—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Solifenacin—Urticaria—Epirubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Solifenacin—Constipation—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Solifenacin—Abdominal pain—Epirubicin—thyroid cancer	0.00119	0.00119	CcSEcCtD
Solifenacin—Feeling abnormal—Doxorubicin—thyroid cancer	0.00115	0.00115	CcSEcCtD
Solifenacin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00114	0.00114	CcSEcCtD
Solifenacin—Hypersensitivity—Epirubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Solifenacin—Urticaria—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Solifenacin—Abdominal pain—Doxorubicin—thyroid cancer	0.00111	0.00111	CcSEcCtD
Solifenacin—Asthenia—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Solifenacin—Pruritus—Epirubicin—thyroid cancer	0.00107	0.00107	CcSEcCtD
Solifenacin—Hypersensitivity—Doxorubicin—thyroid cancer	0.00103	0.00103	CcSEcCtD
Solifenacin—Asthenia—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Solifenacin—Dizziness—Epirubicin—thyroid cancer	0.000999	0.000999	CcSEcCtD
Solifenacin—Pruritus—Doxorubicin—thyroid cancer	0.000989	0.000989	CcSEcCtD
Solifenacin—Vomiting—Epirubicin—thyroid cancer	0.000961	0.000961	CcSEcCtD
Solifenacin—Rash—Epirubicin—thyroid cancer	0.000953	0.000953	CcSEcCtD
Solifenacin—Dermatitis—Epirubicin—thyroid cancer	0.000952	0.000952	CcSEcCtD
Solifenacin—Headache—Epirubicin—thyroid cancer	0.000947	0.000947	CcSEcCtD
Solifenacin—Dizziness—Doxorubicin—thyroid cancer	0.000925	0.000925	CcSEcCtD
Solifenacin—Nausea—Epirubicin—thyroid cancer	0.000898	0.000898	CcSEcCtD
Solifenacin—Vomiting—Doxorubicin—thyroid cancer	0.000889	0.000889	CcSEcCtD
Solifenacin—Rash—Doxorubicin—thyroid cancer	0.000882	0.000882	CcSEcCtD
Solifenacin—Dermatitis—Doxorubicin—thyroid cancer	0.000881	0.000881	CcSEcCtD
Solifenacin—Headache—Doxorubicin—thyroid cancer	0.000876	0.000876	CcSEcCtD
Solifenacin—Nausea—Doxorubicin—thyroid cancer	0.00083	0.00083	CcSEcCtD
